Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society, 41436-41437 [E9-19584]
Download as PDF
41436
Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices
modifying existing facilities as
authorized by a construction permit and
determines it is necessary to either
discontinue operation or to operate with
temporary facilities to continue program
service for a period not more than 30
days. Licensees or permittees of
directional or nondirectional FM, TV or
Class A TV or nondirectional AM must
file a notification and comply with 47
CFR 73.1615(a). Licensees or permittees
of a directional AM station whose
modification does not involve a change
in operating frequency must file a
notification and comply with 47 CFR
73.1615(b). Licensees or permittees of a
directional AM station whose
modification does involve a change in
frequency and determines it is necessary
to discontinue operation for a period not
more than 30 days must file a
notification and comply with 47 CFR
73.1615(d)(2).
Section 73.1615 informal letter
requests (47 CFR § 73.1615). Broadcast
stations (AM, FM, TV or Class A TV
licensees or permittees) must file an
informal letter request under 47 CFR
73.1615(c)(1) when such a station is in
the process of modifying existing
facilities pursuant to 47 CFR 73.1615(a)
or (b) and determines it is necessary to
either discontinue operation or to
operate with temporary facilities to
continue program service for a period of
more than 30 days. Licensees or
permittees that filed notifications under
47 CFR 73.1615(d)(2) but which
determine that it is necessary to
discontinue operation for a period more
than 30 days must file an informal letter
request and comply with 47 CFR
73.1615(d)(1) and (2).
Federal Communications Commission.
Marlene H. Dortch,
Secretary.
[FR Doc. E9–19672 Filed 8–14–09; 8:45 am]
Board of Governors of the Federal Reserve
System, August 12, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9–19630 Filed 8–14–09; 8:45 am]
BILLING CODE: 6712–01–S
FEDERAL RESERVE SYSTEM
mstockstill on DSKH9S0YB1PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
BILLING CODE 6210–01–S
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
VerDate Nov<24>2008
17:55 Aug 14, 2009
Jkt 217001
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than September 10,
2009.
A. Federal Reserve Bank of Atlanta
(Steve Foley, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30309:
1. Heart of Georgia Bancshares, Inc.,
Mount Vernon, Georgia; to acquire 100
percent of the voting shares of The
Tattnall Bank, Reidsville, Georgia.
B. Federal Reserve Bank of San
Francisco (Kenneth Binning, Vice
President, Applications and
Enforcement) 101 Market Street, San
Francisco, California 94105-1579:
1. Golden Pacific Bancorp,
Sacramento, California; to acquire 100
percent of Gold Country Financial
Services, Inc, and thereby indirectly
acquire Gold Country Bank, N.A., both
of Marysville, California.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the twentieth
meeting of the Secretary’s Advisory
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
8:30 a.m. to approximately 6 p.m. on
Thursday, October 8, 2009, and from 8
a.m. to approximately 3:30 p.m. on
Friday, October 9, 2009, at the Hubert H.
Humphrey Building, 200 Independence
Avenue SW., Washington, DC 20201.
The meeting will be open to the public
with attendance limited to space
available. The meeting also will be Web
cast.
The main agenda items involve the
review of three SACGHS draft reports: a
final draft report and its
recommendations on gene patents and
licensing practices along with
comments received on the public
consultation draft circulated earlier this
year; a public consultation draft report
on genetics education and training; and
a revised draft paper on direct-toconsumer genetic testing. The first day
of the meeting will include an extended
period of time for interested members of
the public to provide their perspectives
on gene patents and licensing practices
and their effect on patient access to
genetic tests. Members of the public are
encouraged to contact the SACGHS
Executive Secretary (see below) by
September 15, 2009, if they wish to
participate in this extended public
comment period. Other agenda items
include an update on regulations
implementing the Genetic Information
Nondiscrimination Act, a report on
activities of the Clinical Utility and
Comparative Effectiveness Task Force,
and a brief discussion to initiate the
Committee’s work on ethical issues
related to genomic data sharing.
As always, the Committee welcomes
hearing from anyone wishing to provide
public comment on any issue related to
genetics, health and society. Individuals
who would like to provide public
comment should notify the SACGHS
Executive Secretary, Ms. Sarah Carr, by
telephone at 301–496–9838 or e-mail at
carrs@od.nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite
750, Bethesda, MD 20892. Anyone
planning to attend the meeting who
needs special assistance, such as sign
language interpretation or other
reasonable accommodations, is also
asked to contact the Executive
Secretary.
Under authority of 42 U.S.C. 217a,
section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
and genomic technologies and, as
E:\FR\FM\17AUN1.SGM
17AUN1
Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices
warranted, to provide advice on these
issues. The draft meeting agenda and
other information about SACGHS,
including information about access to
the Web cast, will be available at the
following Web site: https://
oba.od.nih.gov/SACGHS/
sacghs_meetings.html.
Dated: August 10, 2009.
Jennifer Spaeth,
Director, NIH Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19584 Filed 8–14–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSKH9S0YB1PROD with NOTICES
AGENCY: Department of Health and
Human Services.
ACTION: Notice: correction.
Food and Drug Administration
[Docket No. FDA–2008–P–0443]
SUMMARY: The Department of Health and
Human Services (HHS) published a
document in the Federal Register of
July 17, 2009, requesting OMB
reauthorization of the form
‘‘Sterilization of Persons in Federally
Assisted Family Planning Projects.’’ The
document contained an incorrect
citation to the HHS sterilization
regulations; incorrectly identified the
Office of Population Affairs (OPA),
rather than the Public Health Service
(PHS), as the agency within HHS that
administers programs of health services
which are supported by Federal
financial assistance and which are
required to obtain informed consent
from persons undergoing sterilizations;
incorrectly described the form that is
required to be used to obtain informed
consent; and incorrectly referred to the
regulations to which the consent form is
appended as OPA regulations rather
than PHS regulations.
FOR FURTHER INFORMATION CONTACT:
Sherette Funn-Coleman, 202–690–5683.
Corrections:
In the Federal Register of July 17,
2009, in FR Doc. OS–0937–0166, on
page 34757, in the second column,
correct the citation to the sterilization
regulations to read:
Proposed Project: HHS 42 CFR part
50, subpart B; Sterilization of Persons in
Federally Assisted Family Planning
Projects—
In the third column, correct the
‘‘Abstract’’ related to the consent form
to read as follows:
The consent form solicits information
to assure voluntary and informed
consent to persons undergoing
17:55 Aug 14, 2009
Jkt 217001
Dated: August 7, 2009.
Seleda Perryman,
Office of the Secretary, Paperwork Reduction
Act Reports Clearance Officer.
[FR Doc. E9–19566 Filed 8–14–09; 8:45 am]
BILLING CODE 4150–34–P
Sterilization of Persons in Federally
Assisted Family Planning Projects
(July 17, 2009); Correction
VerDate Nov<24>2008
sterilization in programs of health
services which are supported by Federal
financial assistance administered by the
Public Health Service (PHS). The form
provides additional procedural
protections to individuals undergoing
sterilization. In order to obtain informed
consent, the regulation requires that
programs use either the form that is
appended to the PHS regulation or
another consent form approved by the
Secretary.
Determination That DEMADEX
(Torsemide) Injection, 20 Milligrams/2
Milliliter (10 Milligrams/Milliliter) and 50
Milligrams/5 Milliliter (10 Milligrams/
Milliliter), Was Not Withdrawn From
Sale for Reasons of Safety or
Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing its
determination that DEMADEX
(torsemide) injection, 20 milligrams
(mg)/2 milliliter (mL) (10 mg/mL) and
50 mg/5 mL (10 mg/mL), was not
withdrawn from sale for reasons of
safety or effectiveness. This
determination will allow FDA to
approve abbreviated new drug
applications (ANDAs) for torsemide
injection, 20 mg/2mL (10 mg/mL) and
50 mg/5 mL (10 mg/mL), if all other
legal and regulatory requirements are
met.
FOR FURTHER INFORMATION CONTACT:
Nikki Mueller, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6312,
Silver Spring, MD 20993–0002, 301–
796–3601.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417 (the 1984 amendments)), which
authorized the approval of duplicate
versions of drug products approved
under an ANDA procedure. ANDA
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
41437
applicants must, with certain
exceptions, show that the drug for
which they are seeking approval
contains the same active ingredient in
the same strength and dosage form as
the ‘‘listed drug,’’ which is a version of
the drug that was previously approved.
ANDA applicants do not have to repeat
the extensive clinical testing otherwise
necessary to gain approval of a new
drug application (NDA). The only
clinical data required in an ANDA are
data to show that the drug that is the
subject of the ANDA is bioequivalent to
the listed drug.
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
agency withdraws or suspends approval
of the drug’s NDA or ANDA for reasons
of safety or effectiveness, or if FDA
determines that the listed drug was
withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
Under § 314.161(a)(1) (21 CFR
314.161(a)(1)), the agency must
determine whether a listed drug was
withdrawn from sale for reasons of
safety or effectiveness before an ANDA
that refers to that listed drug may be
approved. FDA may not approve an
ANDA that does not refer to a listed
drug.
PharmaForce, Inc., submitted a citizen
petition dated August 5, 2008 (Docket
No. FDA–2008–P–0443), under 21 CFR
10.30 requesting that the agency
determine whether DEMADEX
(torsemide) injection, 20 mg/2 mL (10
mg/mL) and 50 mg/5 mL (10 mg/mL),
was withdrawn from sale for reasons of
safety or effectiveness. DEMADEX
(torsemide) injection is the subject of
NDA 20–137, held by Roche
Pharmaceuticals (Roche) and was
initially approved on August 23, 1993.
DEMADEX is indicated for the
treatment of edema associated with
congestive heart failure, renal disease,
or hepatic disease. Roche notified FDA
on June 16, 2008, that it was no longer
marketing DEMADEX (torsemide)
injection, 20 mg/2 mL (10 mg/mL) and
50 mg/5 mL (10 mg/mL), and the drug
product was moved to the
‘‘Discontinued Drug Product List’’
section of the Orange Book.
FDA has reviewed its records and,
under § 314.161, has determined that
DEMADEX (torsemide) injection, 20 mg/
2 mL (10 mg/mL) and 50 mg/5 mL (10
E:\FR\FM\17AUN1.SGM
17AUN1
Agencies
[Federal Register Volume 74, Number 157 (Monday, August 17, 2009)]
[Notices]
[Pages 41436-41437]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19584]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Notice of Meeting: Secretary's Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92-463, notice is hereby given of the
twentieth meeting of the Secretary's Advisory Committee on Genetics,
Health, and Society (SACGHS), U.S. Public Health Service. The meeting
will be held from 8:30 a.m. to approximately 6 p.m. on Thursday,
October 8, 2009, and from 8 a.m. to approximately 3:30 p.m. on Friday,
October 9, 2009, at the Hubert H. Humphrey Building, 200 Independence
Avenue SW., Washington, DC 20201. The meeting will be open to the
public with attendance limited to space available. The meeting also
will be Web cast.
The main agenda items involve the review of three SACGHS draft
reports: a final draft report and its recommendations on gene patents
and licensing practices along with comments received on the public
consultation draft circulated earlier this year; a public consultation
draft report on genetics education and training; and a revised draft
paper on direct-to-consumer genetic testing. The first day of the
meeting will include an extended period of time for interested members
of the public to provide their perspectives on gene patents and
licensing practices and their effect on patient access to genetic
tests. Members of the public are encouraged to contact the SACGHS
Executive Secretary (see below) by September 15, 2009, if they wish to
participate in this extended public comment period. Other agenda items
include an update on regulations implementing the Genetic Information
Nondiscrimination Act, a report on activities of the Clinical Utility
and Comparative Effectiveness Task Force, and a brief discussion to
initiate the Committee's work on ethical issues related to genomic data
sharing.
As always, the Committee welcomes hearing from anyone wishing to
provide public comment on any issue related to genetics, health and
society. Individuals who would like to provide public comment should
notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at
301-496-9838 or e-mail at carrs@od.nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone
planning to attend the meeting who needs special assistance, such as
sign language interpretation or other reasonable accommodations, is
also asked to contact the Executive Secretary.
Under authority of 42 U.S.C. 217a, section 222 of the Public Health
Service Act, as amended, the Department of Health and Human Services
established SACGHS to serve as a public forum for deliberations on the
broad range of human health and societal issues raised by the
development and use of genetic and genomic technologies and, as
[[Page 41437]]
warranted, to provide advice on these issues. The draft meeting agenda
and other information about SACGHS, including information about access
to the Web cast, will be available at the following Web site: https://oba.od.nih.gov/SACGHS/sacghs_meetings.html.
Dated: August 10, 2009.
Jennifer Spaeth,
Director, NIH Office of Federal Advisory Committee Policy.
[FR Doc. E9-19584 Filed 8-14-09; 8:45 am]
BILLING CODE 4140-01-P